Clinical evidence reveals significantly elevated GSK3β activity alongside suppressed Nrf2 activity in renal biopsy samples from DKD patients, highlighting the therapeutic potential of targeting this pathway (Mohs et al., 2021). This evidence concerns the gene GSK3B and diabetic kidney disease.